HotSpot Therapeutics

Executive Summary

HotSpot Therapeutics is a privately held biotechnology company headquartered in Boston, pioneering an innovative approach to allosteric drug discovery. Founded in 2017, the company focuses on unlocking "natural hotspots"—endogenous on/off switches on proteins—to develop differentiated small molecule therapies. By targeting these regulatory sites, HotSpot aims to achieve high selectivity and efficacy across a range of diseases, with initial programs likely in oncology and immunology. The company's platform leverages advanced computational and structural biology techniques to identify and modulate allosteric sites that are often overlooked by traditional drug discovery methods. Despite being in the pre-clinical stage, HotSpot has attracted significant interest from major pharmaceutical partners, securing collaborations that validate its platform and provide non-dilutive funding. The company's progress has been steady, but it remains at an early phase with no disclosed pipeline candidates or clinical data yet. HotSpot's ability to advance its most promising programs into the clinic will be critical in the near term.

Upcoming Catalysts (preview)

• Q4 2026Announcement of lead IND filing for first program40% success
• Q3 2026New collaboration or partnership expansion with a major pharma55% success
• Q2 2027Disclosure of preclinical data at a major scientific conference50% success